论文信息 - Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia.

Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia.

We have examined the level of c-myc transcripts in prostate tissue obtained from patients with both benign prostatic hyperplasia and adenocarcinoma of the prostate. A significantly higher level of c-myc transcripts is observed in patients with adenocarcinoma (P less than 0.05). In addition, a subset of patients with adenocarcinoma had levels of c-myc transcripts 2-fold higher than the mean level for this group. These preliminary results indicate that the investigation of c-myc levels as a prognostic indicator in prostatic carcinoma is warranted.

[1] P. Hand,et al. Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases , 1984, Nature.

[2] D. Kozbor,et al. Amplification of the c-myc oncogene in one of five human breast carcinoma cell lines. , 1984, Cancer research.

[3] P. Leder,et al. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor , 1983, Cell.

[4] J. Minna,et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines , 1983, Nature.

[5] D. S. Coffey,et al. Prostate tumor biology and cell kinetics--theory. , 1981, Urology.

[6] W. Rutter,et al. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[7] J. Bailar,et al. The histology and prognosis of prostatic cancer. , 1967, The Journal of urology.